Senolytic therapy reduces inflammation in epithelial cells from COPD patients and in smoke-exposure mice
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Senescent cells drive chronic obstructive pulmonary disease (COPD) lung aging and inflammation. The senolytic drug combination dasatinib and quercetin (D+Q) reduced these senescent cells and inflammation in COPD models.
Area Of Science
- Pulmonary Medicine
- Cellular Biology
- Aging Research
Background
- Chronic obstructive pulmonary disease (COPD) is characterized by accelerated lung aging and increased senescent cells.
- Senescent cells contribute to COPD pathology through defective tissue repair and the senescence-associated secretory phenotype (SASP).
- Senolytics, drugs that eliminate senescent cells, have not been studied in COPD.
Purpose Of The Study
- To investigate senescent cell maintenance in COPD airway epithelial cells.
- To evaluate the efficacy of the senolytic combination dasatinib and quercetin (D+Q) in COPD models.
- To assess the impact of D+Q on senescence markers and inflammation.
Main Methods
- Differentiated non-smoker and COPD bronchial epithelial cells at air-liquid interface (ALI).
- Measured senescence markers (p16INKA, p21WAF1) and SASP factors.
- Treated cells and cigarette smoke (CS)-exposed mice with D+Q.
Main Results
- COPD ALI epithelium showed increased senescence markers.
- D+Q treatment reduced senescence markers, proteases, and Th2 cytokines in vitro.
- D+Q treatment in CS-exposed mice reduced senescence burden and lung inflammation (CXCL1).
Conclusions
- COPD patients exhibit increased airway epithelial senescence.
- The senolytic cocktail D+Q effectively clears senescent cells.
- D+Q reduces pulmonary inflammation in COPD models, offering a potential therapeutic strategy.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
• Inhalation of Irritants: Inhaling irritants, especially cigarette smoke, are primary causes of inflammation in COPD. Other irritants can include...
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Chronic obstructive pulmonary disease (COPD) is a group of lung conditions that progressively worsen over time, including chronic bronchitis and emphysema. This cluster of diseases collectively leads to a gradual and irreversible decline in lung function over time.
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...